Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: Links to cognitive decline

Journal of Psychiatry and Neuroscience

Volumn 40, Issue 3, 2015, Pages 151-161

  Gourmaud, Sarah ^a,c   Paquet, Claire ^a,b,c   Dumurgier, Julien ^a,b,c   Pace, Clarisse ^a   Bouras, Constantin ^d,e   Gray, Françoise ^c   Laplanche, Jean Louis ^c   Meurs, Eliane F ^f   Mouton Liger, François ^a,c   Hugon, Jacques ^a,b,c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔPITAL FERNAND WIDAL   (France)

^c Department of Histology ^*  (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 10; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 9; PEPTIDE FRAGMENT; STRESS ACTIVATED PROTEIN KINASE 1;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORYLATION; RETROSPECTIVE STUDY; SENILE PLAQUE; WESTERN BLOTTING; AMYLOID PLAQUE; BRAIN; CEREBROSPINAL FLUID; COHORT ANALYSIS; DISEASE COURSE; ENZYMOLOGY; METABOLISM; PATHOLOGY; PSYCHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 10; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; TAU PROTEINS;

EID: 84928725863     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140062     Document Type: Article

References (47)

1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009;118:5-36.
2. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
3. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet 2010;19:R12-R20.
4. Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
5. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimertype pathologic changes in the brain. Arch Neurol 2009;66:382-389.
6. Mouton-Liger F, Paquet C, Dumurgier J, et al. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer’s disease. Biol Psychiatry 2012;71:829-835.
7. Dumurgier J, Mouton-Liger F, Lapalus P, et al. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer’s disease. PLoS ONE 2013;8:e53587.
8. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
9. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
10. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008;27:6245-6251.
11. Wei W, Norton DD, Wang X, et al. Abeta 17-42 in Alzheimer’s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 2002;125:2036-2043.
12. Bogoyevitch MA. The isoform-specific functions of the c-Jun Nterminal kinases (JNKs): differences revealed by gene targeting. BioEssays 2006;28:923-934.
13. Colombo A, Bastone A, Ploia C, et al. JNK regulates APP cleavage and degradation in a model of Alzheimer’s disease. Neurobiol Dis 2009;33:518-525.
14. Yoon SO, Park DJ, Ryu JC, et al. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron 2012;75:824-837.
15. Tamagno E, Guglielmotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 2008;104:683-695.
16. Lagalwar S, Berry RW, Binder LI. Relation of hippocampal phosphoSAPK/JNK granules in Alzheimer’s disease and tauopathies to granulovacuolar degeneration bodies. Acta Neuropathol 2007;113:63-73.
17. Zhu X, Raina AK, Rottkamp CA, et al. Activation and redistribution of C-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease. J Neurochem 2001;76:435-441.
18. Zhu X, Ogawa O, Wang Y, et al. JKK1, an upstream activator of JNK/ SAPK, is activated in Alzheimer’s disease. J Neurochem 2003;85:87-93.
19. Kuan CY, Whitmarsh AJ, Yang DD, et al. A critical role of neuralspecific JNK3 for ischemic apoptosis. Proc Natl Acad Sci U S A 2003;​ 100:​15184-15189.
20. Brecht S, Kirchhof R, Chromik A, et al. Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 2005;21:363-377.
21. Yang DD, Kuan CY, Whitmarsh AJ, et al. Absence of excitotoxicityinduced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997;389:865-870.
22. Morishima Y, Gotoh Y, Zieg J, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the C-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001;​ 21:7551-7560.
23. Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101:665-670.
24. Zhu X, Lee HG, Raina AK, et al. The role of mitogen-activated protein kinase pathways in Alzheimer’s disease. Neurosignals 2002;11:270-281.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-944.
26. Dumurgier J, Vercruysse O, Paquet C, et al. Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting. Alzheimers Dement 2013;9:406-413.
27. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
28. Mouton-Liger F, Paquet C, Dumurgier J, et al. Oxidative stress increases BACE1 protein levels through activation of the PKReIF2alpha pathway. Biochim Biophys Acta 2012;1822:885-896.
29. Bose A, Mouton-Liger F, Paquet C, et al. Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer’s disease. Brain Pathol 2011;21:189-200.
30. Paquet C, Mouton-Liger F, Meurs EF, et al. The PKR activator PACT is induced by Abeta: involvement in Alzheimer’s disease. Brain Pathol 2012;22:219-229.
31. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
32. Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer’s disease. Evidence for heterogeneity. Brain 1992;115:735-748.
33. Pei JJ, Braak E, Braak H, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer’s disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis 2001;3:41-48.
34. Hoozemans JJ, van Haastert ES, Nijholt DA, et al. The unfolded protein response is activated in pretangle neurons in Alzheimer’s disease hippocampus. Am J Pathol 2009;174:1241-1251.
35. Bossers K, Wirz KT, Meerhoff GF, et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer’s disease. Brain 2010;133:3699-3723.
36. Chami L, Buggia-Prevot V, Duplan E, et al. Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012;287:24573-24584.
37. Dever TE. Gene-specific regulation by general translation factors. Cell 2002;108:545-556.
38. Proud CG. eIF2 and the control of cell physiology. Semin Cell Dev Biol 2005;16:3-12.
39. O’Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008;60:988-1009.
40. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760-2770.
41. Kim W, Lee S, Hall GF. Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert. FEBS Lett 2010;584:3085-3088.
42. Kim W, Lee S, Jung C, et al. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 2010;19:647-664.
43. Simon D, Garcia-Garcia E, Royo F, et al. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 2012;586:47-54.
44. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov Today 2004;9:932-939.
45. Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 2005;26:455-461.
46. Sclip A, Antoniou X, Colombo A, et al. C-Jun N-terminal kinase regulates soluble Abeta oligomers and cognitive impairment in AD mouse model. J Biol Chem 2011;286:43871-4380.
47. Zhu PJ, Huang W, Kalikulov D, et al. Suppression of PKR promotes network excitability and enhanced cognition by interferongamma-mediated disinhibition. Cell 2011;147:1384-1396.